FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

US FDA grants orphan drug designation to Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns to treat multiple myeloma: Paris Friday, August 1, 2025, 09:00 Hrs [IST] The US ...

Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment ...

G protein-coupled receptor, class C, group 5, member D (GPRC5D) loss after chimeric antigen receptor (CAR) T-cell therapy in ...

Paris: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for SAR446523, an ...

Panelists discuss updated safety findings from GPRC5D-targeted bispecific therapy in relapsed/refractory multiple myeloma, ...

Panelists discuss updated MonumenTAL-1 trial data demonstrating high response rates and prolonged survival with ...

Patients have been asking me about a recently published article that suggests a "'potential cure"' for myeloma is at hand.